Skip to content

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Fan Bu, Lan Qin, Zhengchi Lou, Yanfang Xie, Shaojian Zhang, Lile Xiong, Yi Wen

Drug Design, Development and Therapy 2026 DOI: 10.2147/dddt.s609327 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Narrative review Peer reviewed
Population Patients with depressive disorders
Topics Depression Psychedelic-assisted therapy
Keywords Bipolar depression Depressive disorders Neuroactive steroids Rapid-acting antidepressants
Key findings Progress in depression pharmacotherapy depends on integrating novel drug classes with improved use of established agents, while remaining sensitive to differences among unipolar depression, bipolar depression, and treatment-resistant depression.

Abstract

Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability limitations reduce the practical value of conventional monoaminergic strategies. This clinically oriented narrative review examines next-generation pharmacotherapy for depressive disorders from a drug-centered and mechanism-informed perspective. A targeted literature search was conducted across major biomedical and psychological databases and was supplemented by regulatory documents, prescribing information, pharmacogenomic recommendations, and selected real-world evidence. Representative next-generation approaches include N-methyl-D-aspartate (NMDA) receptor modulators and other rapid-acting agents, dextromethorphan-bupropion, multimodal antidepressants, neuroactive steroid-related therapies such as brexanolone and zuranolone, psychedelic-assisted pharmacotherapy, kappa-opioid receptor antagonists, and bipolar-relevant mood-stabilizing pharmacotherapies. The review also discusses mechanism-informed optimization of available drugs, including repurposing, augmentation, rational combination pharmacotherapy, dose and sequencing strategies, maintenance-oriented prescribing, and measurement-based care. Pharmacogenomics, pharmacokinetic/pharmacodynamic variability, and clinical stratification are considered as practical components of precision pharmacotherapy. Current evidence suggests that progress in depression pharmacotherapy depends not only on developing new compounds, but also on improving treatment selection, sequencing, monitoring, tolerability management, and sustained use in heterogeneous clinical populations. A next-generation framework should therefore integrate novel drug classes with improved use of established agents, while remaining sensitive to differences among unipolar depression, bipolar depression, and TRD.

Comparable studies

Other narrative reviews on depression, most cited first.

Study Year Design Participants
Synaptic Dysfunction in Depression: Potential Therapeutic Targets 2012 Review
Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse 2003 Review
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression 2021 Review
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population 2019 Integrative review
Sudarshan Kriya Yogic Breathing in the Treatment of Stress, Anxiety, and Depression: Part II—Clinical Applications and Guidelines 2005 Review

Citations in the library

Cites 22

and 17 more in the library

Related reading

Explore topics

Depression Psychedelic-assisted therapy Addiction